Vaccines Submission Guide: MDPI Process (2026)

Vaccines is not a stronger version of a subscription vaccine journal, and it is not a weaker one. It is a different model. MDPI built it around speed and soundness-based review: the editorial question is whether the work is methodologically sound and within scope, not whether it ranks among the most selective findings of the year. That model shapes everything about how you should prepare the package.

Two consequences matter most. First, the journal is organized by topic section and runs a heavy special-issue program across vaccine subfields, so scope fit is assessed against a specific section or special-issue call rather than a vague "is this interesting" bar. Second, the pre-check is fast and partly template-driven, so completeness is rewarded and incompleteness is punished early. A technically excellent immunogenicity study with a missing trial-registration number or animal-ethics statement can be returned before a reviewer ever sees it, while a competent, complete, in-scope study moves quickly.

The vaccinology-specific upside: Vaccines casts a wide net across the field, from antigen design and adjuvants through preclinical challenge models, clinical immunogenicity and efficacy trials, vaccine effectiveness, vaccine safety and pharmacovigilance, and vaccine hesitancy and confidence research. If your study is a well-designed vaccine-effectiveness analysis, a safety surveillance signal, or a hesitancy survey with a real sampling frame, this is a venue that treats those as core science rather than as secondary content.

The catch is that the same breadth means a section editor still has to place your work in a specific subfield, so a vague "immune response to a vaccine" framing is not enough.

The core fit for most submissions is the original research article. It works best when the vaccine question is central, the immune readout connects to a protection or efficacy outcome, the methods are reproducible from the text, and the declarations and reporting package are complete on first upload.

Ask these questions before you submit:

• is the vaccine the actual subject of the paper, or is the vaccine antigen a tool for studying a general immunology question?
• does the immunogenicity readout connect to efficacy, challenge, protection, or mechanism, or does the paper stop at antibody titers?
• can a reader reproduce the methods, including the immunization schedule, doses, and assays, from the manuscript and supplementary files alone?
• are the ethics, consent, trial-registration, and data statements complete and specific, or are they still stub text?

If the answers are uncertain, the pre-check problem is usually more important than the science problem.

The pre-check editor is answering a short list of questions fast.

On scope, the editor asks whether the manuscript belongs in a vaccine journal and in which section or special issue. If the vaccine relevance is thin or bolted on, or if the work is really a basic-immunology paper that happens to use a vaccine antigen, the paper is redirected or returned. On soundness, the question is whether the methods are reproducible and the analysis appropriate.

Vaccines does not require the finding to be field-defining, but it does require the immunization schedule, assays, sample sizes, and statistical analysis to be reported in full.

On integrity, the editor checks whether ethics approvals, consent, clinical-trial registration, image-integrity expectations, and data availability are all in order. MDPI runs integrity and plagiarism checks at pre-check, and gaps here trigger fast returns. A vaccine-effectiveness or clinical-immunogenicity study with no registration number is a classic fast return. On completeness, the editor looks for the declarations block. A manuscript missing Author Contributions, Funding, or Conflicts of Interest reads as not ready, even when the immunology is fine.

Here is the part authors underestimate: the editor is reading your abstract for the outcome, not just the immune readout. An abstract that ends at "we observed a robust antibody response" reads as incomplete, because the reviewer's first question is "robust enough to do what?" The abstracts that move fast name the protective or efficacy consequence of the immune response, even when that consequence is a challenge-model result rather than a clinical endpoint.

Manuscript structure: Vaccines expects a defined section set: Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions, plus the declarations block. Original research and systematic reviews need a structured abstract of around 200 words under Background/Objectives, Methods, Results, and Conclusions headings. The abstract is the first thing the pre-check editor reads, so the vaccine question, the immune readout, and the outcome all need to be visible there.

Reporting and methods readiness: Provide full experimental detail so results can be reproduced, including the immunization schedule, doses, routes, adjuvants, assays, and the strain or antigen design, and follow the design-appropriate guideline: CONSORT for randomized vaccine trials, STROBE for observational vaccine-effectiveness and safety studies, PRISMA for systematic reviews and meta-analyses with a registered protocol, ARRIVE for animal challenge and preclinical work. A clinical or effectiveness paper that does not map cleanly onto its reporting checklist is the most common reviewer-stage friction point.

Declarations and ethics: Draft the Institutional Review Board statement, Informed Consent statement, clinical-trial registration number, Author Contributions (by initials), Funding, Data Availability, and Conflicts of Interest sections before you upload. These are not post-acceptance paperwork at MDPI; they are pre-check gates. For animal challenge studies, the animal-ethics statement with an approval identifier is non-negotiable.

Figures, supplementary, and immunogenicity assets: Provide the trial flow or participant-disposition diagram where the design calls for one, antibody-titer and challenge-study figures with the assay and the dilution series labeled, and per-group sample sizes visible on every immunogenicity plot. Survival or protection curves from challenge models should report the statistical test and the n per arm.

A graphical abstract is optional but commonly used; if supplied, it should be a high-resolution PNG, JPEG, or TIFF at a minimum of 560 by 1100 pixels. Supplementary materials should carry the gating strategies, raw titer tables, extended assay protocols, and survey instruments that would slow the main narrative. ORCID is expected for the submitting author, and the system will ask for suggested reviewers.

In our pre-submission review work with Vaccines manuscripts, four failure patterns generate the most consistent pre-check returns and reviewer friction, and they are testable against your own manuscript before you upload. Across the Vaccines and vaccine-journal manuscripts we have reviewed, these four account for the large majority of the pre-check returns we see reported, and they cut across the field rather than clustering in one subfield.

The four patterns, summarized:

1. Immunogenicity with no outcome: antibody titers reported in isolation, with no efficacy, challenge, protection, or mechanism.
2. Scope-thin vaccine framing: a basic-immunology study with a vaccine antigen added late, so the section editor cannot place it.
3. Overstated small-sample surveys: hesitancy or confidence work whose conclusions outrun the sampling frame.
4. Incomplete ethics, registration, and reporting: missing trial-registration numbers, ethics identifiers, or the design-appropriate checklist.

Across our Vaccines pre-submission reviews, the pattern that surprises authors most is that the MDPI pre-check is not a quality filter in the Nature sense; it is a completeness-and-fit filter. The manuscripts that get returned fastest are rarely bad science. They are competent studies whose vaccine scope angle, immunogenicity-to-outcome link, declarations block, or reporting compliance is not ready for a fast, template-driven screen. Manuscripts coming through pre-submission review for Vaccines split cleanly along these four lines.

Immunogenicity data with no efficacy, challenge, or mechanism

Pattern 1: titers without a consequence. The single most common pattern we see is a manuscript that stops at antibody titers. The study measures a serum IgG response, or a T-cell readout, after immunization, and then concludes that the vaccine "elicited a strong immune response" without connecting that response to protection, a challenge-model outcome, neutralization, or a mechanism.

Reviewers at a vaccine journal read immunogenicity as a means, not an end: the question is always "does this immune response do something?" The testable version of this failure: look at your own Results, and confirm that at least one figure ties the immune readout to an outcome, a challenge study with survival or viral-load data, a correlate of protection, neutralizing-antibody function, or a mechanistic link.

If every figure is a titer plot and the protection question lives only in the Discussion as a future direction, the paper is not yet a Vaccines paper. The fix is usually to add the challenge or neutralization experiment, or to reframe the manuscript honestly as a communication of preliminary immunogenicity.

Check whether your Vaccines immunogenicity data connects to a protection outcome

Scope-thin vaccine framing that the section editor cannot place

Pattern 2: the vaccine is a tool, not the subject. The second pattern is a manuscript whose vaccine relevance is downstream rather than central. The study is really a basic-immunology, adjuvant-chemistry, antigen-structural-biology, or bioinformatics paper, and a vaccine antigen or a vaccination model has been added so the work can target a vaccine journal.

Vaccines is section-based and runs a heavy special-issue program, so the pre-check editor has to place the manuscript in a specific subfield. When the vaccine question is not the actual subject, the section assignment fails and the paper is returned or redirected fast.

The testable version of this failure: read your own abstract and introduction, and ask whether a section editor could name the vaccine subfield, antigen design, adjuvant, delivery system, effectiveness, safety, or hesitancy, from the first paragraph alone.

If the vaccine angle only appears in the discussion, or only as an application, the framing is too thin for the pre-check, and the fix is to rebuild the introduction and abstract around the vaccine question rather than around the underlying immunology method.

Small-sample hesitancy or confidence surveys with overstated conclusions

Pattern 3: the survey conclusion outruns the sample. The third pattern is specific to the social-science end of vaccinology, and it is one Vaccines sees a lot because it welcomes vaccine-hesitancy and vaccine-confidence research. The study is a survey of a few hundred respondents, often a convenience sample from one clinic or one online panel, and the conclusions generalize to a national population, a policy recommendation, or a causal claim about what drives hesitancy.

Reviewers return these for the gap between the sampling frame and the conclusion. The testable version: confirm your sample size, recruitment method, and response rate support the population your conclusions describe, that the survey instrument is validated or its limitations are stated, and that a confidence-interval or effect-size report accompanies every headline percentage rather than a bare proportion.

A vaccine-confidence opinion piece with no data, or a hesitancy survey whose conclusion outruns its sampling frame, is the version of this failure that gets returned fastest. If your discussion makes a policy claim, the methods must carry a representative sample and a statistical analysis that earns it.

Check whether your Vaccines survey conclusions match the sampling frame

Incomplete ethics, trial registration, and reporting checklists

The fourth pattern is a declarations and reporting block that is missing, generic, or left as stub text. MDPI treats the Institutional Review Board statement, Informed Consent statement, animal-ethics statement, clinical-trial registration number, and Data Availability Statement as pre-check gates, not as paperwork to finalize after acceptance.

We repeatedly see human vaccine trials with no registration number, animal challenge studies with no ethics approval identifier, and a Data Availability Statement that reads only "data available on request" with no repository for the titer data. We also see clinical and effectiveness studies that do not map onto CONSORT or STROBE: a randomized trial with no flow diagram, an effectiveness study with no STROBE checklist, animal work that ignores ARRIVE.

Because the pre-check is fast, a single missing statement can return the manuscript before review.

The testable version: for every claim in your paper that touches patients, tissue, or animals, confirm there is a corresponding ethics statement with a real approval identifier; confirm any clinical study carries a registration number; identify the guideline that matches your design and walk your manuscript against every checklist item; and confirm your Data Availability Statement names where the data actually lives.

Each of these is something you can check against your own draft before you commit the submission. This guide tells you what Vaccines editors look for; the review tells you whether YOUR paper passes the pre-check before you upload.

Across the 40 manuscripts and more Manusights has reviewed targeting vaccine and immunology journals, including Vaccines and its open-access and subscription peers, the immunogenicity-with-no-outcome pattern is the single most common reason a technically sound paper still draws a major-revision or return. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts. Run a [Vaccines submission package check](/ai-review?

target_journal=Vaccines&source_blog=vaccines-submission-guide&primary_concern=submission_readiness) to see whether your scope framing, immunogenicity-to-outcome link, declarations block, and reporting compliance will clear the MDPI pre-check.

Vaccines reports a median first decision near 18 days and median acceptance-to-publication near 2.8 days. Treat these as planning ranges, not promises: clinical trial and large vaccine-effectiveness manuscripts often run longer because reviewer search takes time in specialized subfields.

• Day 0: Submission via SuSy. The portal accepts the package and routes it to the section or special-issue editor for pre-check.

• Days 1 to 3: Editorial pre-check. The editor screens scope fit, the immunogenicity-to-outcome link, ethics and registration completeness, integrity and plagiarism checks, and basic soundness.

The fastest returns happen here, before any reviewer is invited.

• Days 3 to 7: Reviewer invitation. Manuscripts that pass pre-check enter single-blind reviewer search, typically targeting two or more reviewers in the relevant vaccine subfield.

• Days 7 to 18: Peer review and first decision. Reviewer reports return and the editor issues the first decision, with a median near 18 days from submission.

Major revision is the most common outcome for papers that clear pre-check.

• Days 18 to 35: Revision and acceptance. Revisions are usually requested on a short clock; resubmission and a second review cycle commonly land acceptance inside a few weeks for in-scope, complete packages.

• Days 35 to 40: Production and publication. Acceptance to publication runs near 2.8 days at median, so the slow part of the calendar is reviewer search and revision, not production.

What slows a Vaccines decision in practice

Two things stretch the timeline past the 18-day median, and both are predictable. Reviewer search is slower for niche subfields: a structural-vaccinology or adjuvant-chemistry paper waits longer than a COVID-19 effectiveness study because the reviewer pool is smaller. And manuscripts that clear pre-check with a thin immunogenicity-to-outcome link tend to draw a major-revision asking for the protection or challenge data the paper should have led with, which adds a full review cycle.

The honest read: the median is real for complete, in-scope packages, but a paper that hides its weakest section behind a strong titer figure usually pays for it in a longer revision, not a faster acceptance.

This guide was researched and built from primary sources: the sources we checked include the Vaccines Instructions for Authors, the journal's aims-and-scope and editorial-process pages, MDPI's research and publication ethics policy, and Manusights pre-submission review patterns from vaccine and immunology manuscripts deciding between Vaccines and peer journals. We reviewed and compared current MDPI author guidance with recent Manusights work reviews from authors weighing Vaccines, npj Vaccines, Vaccine (Elsevier), Human Vaccines & Immunotherapeutics, and Frontiers in Immunology. Last reviewed by the Manusights immunology editorial team on 2026-06-07.

Source limitations: MDPI can update the APC, article-format details, abstract caps, and editorial-process numbers after this review date, so verify final administrative details against the official Vaccines author pages before upload. Median timelines are reported by the journal and vary by subfield. Use this guide for the decision the official instructions cannot answer: whether your vaccine scope framing, immunogenicity-to-outcome link, declarations block, and reporting compliance are ready for the MDPI pre-check.

• Vaccines journal overview and metrics
• Best immunology journals
• Frontiers in Immunology submission guide
• Frontiers in Immunology journal metrics
• Rejected from a vaccine journal, where next?

Before you upload, run your manuscript through a Vaccines submission readiness check to catch the scope, immunogenicity-link, ethics, and reporting gaps the MDPI pre-check filters for. The check is free to run and takes a single upload.